Autologous dendritic cell immunotherapy plus chemotherapy in metastatic castration-resistant prostate cancer
JAMA — Vogelzang NJ, Beer TM, Gerritsen W, et al. | February 14, 2022
The efficacy and safety of DCVAC/PCa, an active cellular immunotherapy, are investigated in men with metastatic castration-resistant prostate cancer (mCRPC).
A randomized clinical trial of 1,182 patients.
Overall survival (OS) did not differ between the DCVAC/PCa and placebo groups, with median OS of 23.9 and 24.3 months, respectively.
Treatment-emergent adverse events occurred in 9.2% and 12.7% of patients in DCVAC/PCa and placebo arms, respectively.
No extension in OS occurred in correlation with receiving DCVAC/PCa combined with docetaxel plus prednisone and continuing it as maintenance treatment; patients with mCRPC well tolerated the treatment.
Researchers emphasize identification of factors linked with the efficacy of immunotherapy to better select patients and thus prolong OS.
Read the full article on JAMA